查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1372782

組學實驗室服務市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按服務、服務頻率、業務、最終用途、地區和競爭細分

Omics Lab Services Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Service, By Frequency Of Service, By Business, By End Use, By Region and Competition
出版日期: | 出版商: TechSci Research | 英文 178 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2022 年，全球組學實驗室服務市場價值高達 712.3 億美元，預計到 2028 年將實現 9.53% 的強勁年複合成長率 (CAGR)。組學實驗室服務市場因充滿活力和活力而脫穎而出。不斷發展的組學科學領域中不可或缺的一部分。

在這個市場中，提供​​了各種各樣的服務，涵蓋從基因組學到蛋白質組學、代謝組學等的一切。這些服務在揭示生物系統的複雜性、揭示遺傳變異以及深入研究用於疾病診斷和治療的生物標記方面發揮關鍵作用。

市場的成長受到幾個關鍵因素的推動，包括：

市場概況
預測期 2024-2028
2022 年市場規模 712.3億美元
2028 年市場規模 1239.9億美元
2023-2028 年年複合成長率 9.53%
成長最快的細分市場 癌症
最大的市場 北美洲
  • 1.對個人化醫療的需求激增：對個人化醫療的需求不斷成長，推動了組學實驗室服務的擴展，因為它們有助於根據個人基因圖譜客製化醫療治療。
  • 2.高通量技術的進步：高通量技術的不斷進步提高了組學實驗室服務的效率和有效性，使研究人員能夠快速、準確地分析大量生物資料。
  • 3.全面資料分析的需求：組學實驗室服務對於全面分析生物資料是不可或缺的，這使得它們在藥物發現、農業和環境研究等各個領域都至關重要。

隨著對精準醫學的追求和對生物系統更深入理解的加強，組學實驗室服務市場不斷擴大其能力，並對許多科學學科產生重大影響。

主要市場促進因素

基因組數據擴大融入臨床工作流程

將基因組學資料整合到臨床工作流程中正在推動醫療保健領域的重大變革，也是組學實驗室服務市場的關鍵驅動力。這種整合正在徹底改變醫療保健的實踐方式，從疾病診斷和治療選擇到監測患者結果。有幾個因素導致將基因組學資料融入臨床實踐及其對組學實驗室服務的後續影響變得越來越重要。首先，基因組資料提供了對個體基因組成的全面了解。這包括識別遺傳變異、突變和疾病傾向。這些資訊對於根據每位患者獨特的基因譜客製化醫療和干涉措施非常寶貴，這一概念被稱為精準醫學。隨著基因組學資料變得更容易獲取和負擔得起，將其整合到臨床工作流程中變得越來越實用和可取。其次，基因組資料在疾病診斷和風險評估中發揮關鍵作用。它使醫療保健提供者能夠識別與各種醫療狀況相關的遺傳標記，從而實現早期疾病檢測和個人化治療策略。例如，基因組資料可以幫助預測個體對某些癌症、心血管疾病或罕見遺傳疾病的易感性。第三，高通量定序技術和生物資訊學工具的進步使得快速且準確地產生和解釋基因組資料變得更加可行。這有助於將基因組學資訊無縫整合到臨床決策過程中。組學實驗室服務提供者處於這些技術進步的最前沿，提供有效處理、分析和解釋基因組資料所需的專業知識和基礎設施。

直接面對消費者的組學採用率不斷上升

直接面對消費者 (DTC) 組學服務的日益普及極大地推動了組學實驗室服務市場的成長。 DTC 組學服務使個人能夠直接從專業實驗室存取和解釋其遺傳、基因組和其他組學訊息，而無需醫療保健提供者中介。由於幾個令人信服的因素，這一趨勢得到了發展，對消費者和組學實驗室服務產業產生了深遠的影響。

首先，DTC 組學服務為消費者提供了有關其基因組成和健康傾向的無與倫比的見解。這種可及性和透明度使個人能夠在管理自己的健康、做出明智的生活方式選擇和考慮個性化的預防措施方面發揮積極作用。隨著消費者變得更加注重健康並對自己的遺感測到好奇，對這些服務的需求激增。其次，DTC組學服務的便利性怎麼強調也不為過。消費者可以輕鬆地線上訂購基因檢測試劑盒，在家中收集樣本，並將其發送到專門的組學實驗室進行分析。這種簡化的流程消除了諸如需要醫療保健提供者處方和多次就診等障礙，使組學測試比以往任何時候都更容易進行。第三，DTC組學服務的激增擴大了組學實驗室服務提供者的市場。這些專業實驗室在處理和分析消費者樣本產生的大量資料方面發揮關鍵作用。他們提供確保資料準確性、隱私和安全性的專業知識，這對消費者的信任至關重要。此外，DTC 組學服務營造了資料共享和研究參與的環境。許多消費者選擇將他們的匿名資料貢獻給研究項目，進一步推進科學知識，並有可能帶來基因組學和個人化醫療的突破。組學實驗室服務提供者是管理和分析這些廣泛資料集的關鍵推動者。

然而，DTC 組學服務的成長也引發了組學實驗室必須應對的道德、隱私和監管方面的考慮。確保資料安全、隱私保護和對結果負責的解釋至關重要。總之，DTC 組學服務的日益普及使基因組和組學資訊的獲取更加民主化，對消費者和組學實驗室服務市場產生了深遠的影響。隨著人們擴大尋求了解自己的基因組成及其對健康和血統的影響，組學實驗室服務提供者準備在滿足這一需求方面發揮關鍵作用，同時也為科學研究和個人化醫療的進步做出貢獻。

對早期疾病診斷測試的需求不斷成長

在早期疾病診斷測試需求不斷成長的推動下，組學實驗室服務市場正在經歷強勁成長。這種需求激增是由幾個相互關聯的因素推動的，這些因素強調了組學實驗室服務在早期疾病檢測和預防領域的關鍵作用。

首先，人們越來越認知到早期疾病診斷對患者預後的深遠影響。早期發現可以及時介入和治療，通常是在疾病處於更容易控制和治癒的階段時。因此，醫療保健系統、臨床醫生和患者越來越重視早期診斷測試，以改善預後和存活率。其次，組學技術的進步徹底改變了診斷測試領域。基因組學、蛋白質組學和代謝組學等技術可以對與各種疾病相關的生物標記進行全面、精確的分析。這些技術提供了對疾病的分子和遺傳基礎的深入了解，提高了診斷準確性並促進了標靶治療的開發。第三，癌症、糖尿病和心血管疾病等慢性病和與生活方式相關的疾病盛行率不斷上升，增加了早期診斷測試的必要性。這些疾病通常在早期階段悄無聲息地進展，因此透過生物標記分析進行早期檢測成為疾病管理和預防的重要策略。

此外，醫療保健政策和公共衛生措施擴大提倡定期篩檢和早期診斷測試，作為預防性醫療保健的一部分。對主動健康管理和疾病預防的重視導致對組學實驗室服務提供者提供的診斷服務的需求激增。此外，COVID-19 大流行凸顯了早期疾病診斷的重要性。快速診斷測試和 SARS-CoV-2 病毒基因組定序有助於識別和控制病毒的傳播。這項經驗凸顯了組學實驗室服務在應對新出現的傳染病和促進及時的公共衛生干涉方面可以發揮的關鍵作用。總之，對早期疾病診斷測試的需求不斷成長是組學實驗室服務市場的一個引人注目的驅動力。隨著醫療保健系統和患者越來越認知到早期檢測的價值，組學實驗室服務提供者將在提供準確、及時的診斷解決方案、最終改善患者治療結果和公共衛生方面發揮關鍵作用。

技術進步

技術進步是組學實驗室服務市場成長和發展的驅動力。這些進步跨越多個維度，包括實驗室儀器、資料分析、高通量技術和自動化方面的創新。它們對組學實驗室服務的影響是深遠且多方面的。首先，技術進步顯著提高了組學分析的準確性和效率。例如，高通量定序平台透過實現快速且經濟高效的 DNA 和 RNA 定序，徹底改變了基因組學研究和診斷。這為研究人員和醫療保健提供者打開了大量資訊的大門，促進了精確診斷、治療選擇和疾病監測。其次，自動化和機器人技術簡化了實驗室工作流程，提高了通量並減少了人為錯誤的可能性。自動化液體處理系統、樣品製備機器人和高內涵成像系統已成為組學實驗室服務的組成部分，提高了可靠性和可重複性。

第三，資料分析和生物資訊學的進步對於管理組學技術產生的大量資料至關重要。機器學習演算法、大資料分析和雲端運算加速了組學資料的解釋，從而能夠識別有意義的模式、生物標記和治療標靶。此外，小型化和微流體技術使得緊湊型攜帶式晶片實驗室設備的開發成為可能。這些創新在即時診斷和資源有限的環境中特別有價值，將組學實驗室服務的範圍擴大到不同的醫療保健環境。此外，技術進步促進了多個組學學科的整合，例如基因組學、蛋白質組學和代謝組學。這種多組學方法提供了對生物系統和疾病的整體了解，提供更全面的診斷見解和個人化治療策略。

在精準醫學時代，技術進步使得基於個體獨特的組學特徵的標靶療法的開發成為可能。這種以患者為中心的方法正在重塑醫療保健服務，其核心是組學實驗室服務。總之，技術進步透過提高組學分析的精度、效率和範圍來推動組學實驗室服務市場。這些創新正在推動個人化醫療領域的發展，並擴大組學實驗室服務在醫療保健、研究和診斷領域的應用，最終改善患者的治療效果和科學進步。

主要市場挑戰

缺乏熟練的專業人員

組學實驗室服務市場正面臨熟練專業人員短缺的重大挑戰。這項挑戰是多方面的，會影響該行業充分利用組學技術潛力並滿足不斷成長的服務需求的能力。首先，組學分析的複雜性需要專門的訓練和專業知識。該領域的專業人員需要對分子生物學、生物資訊學、儀器和資料分析有深入的了解。隨著技術和方法的快速進步，跟上最新發展至關重要。不幸的是，具有這種專業水平的專業人員存在缺口。其次，生物資訊學領域的專業人才短缺尤為明顯。管理和解釋組學技術產生的大量資料需要熟練生物資訊學工具和資料分析。生物資訊學家和計算生物學家的稀缺可能會導致資料分析出現瓶頸，從而導致研究和診斷的延誤。此外，組學科學的跨學科性質需要各領域的專家之間的合作，包括生物學、化學、資訊學和臨床研究。缺乏能夠跨這些學科有效溝通和協作的專業人員，阻礙了組學技術與醫療保健和研究的無縫整合。

組學專業人員的教育和培訓管道也面臨挑戰。大學和培訓課程必須跟上組學技術的快速發展，以培養具備相關技能的畢業生。此外，實踐培訓機會和指導計劃對於彌合學術知識和實際實驗室技能之間的差距至關重要。此外，全球對熟練組學專業人員的競爭加劇了這項挑戰。生技和製藥公司、學術機構和醫療保健提供者都在爭奪同一人才庫，創造了一個可能推高勞動成本的競爭環境。解決組學實驗室服務市場熟練專業人員的短缺問題對於該行業的持續成長和創新至關重要。擴大教育計畫、提供持續教育機會和促進跨學科合作等措施可以幫助緩解這項挑戰，並確保組學技術在醫療保健、研究和診斷領域的潛力得到充分發揮。

組學技術實施緩慢

組學技術的緩慢實施對組學實驗室服務市場構成了重大挑戰。這項挑戰是多方面的，包含阻礙組學技術在研究、診斷和醫療保健中採用和整合的各種因素。首先，組學領域的技術進步很快，跟上最新的創新對於實驗室和醫療機構來說可能具有挑戰性。組學技術不斷發展，引進新技術、儀器和分析方法。這種快速發展可能會對一些可能缺乏資源或基礎設施來快速實施和驗證這些技術的實驗室造成障礙。其次，組學資料產生和分析的複雜性不僅需要專門的設備，還需要開發客製化的實驗室工作流程和資料管理系統。這些基礎設施組件的緩慢適應可能會阻礙組學技術的有效部署，導致研究和診斷的延遲。第三，監管和倫理的考量是組學技術實施緩慢的一個原因。確保遵守與資料隱私、樣本處理和臨床驗證相關的法規至關重要，但可能耗費時間和資源。此外，解決有關組學資料使用的倫理問題，特別是在基因組學等領域，可能會帶來延遲這些技術採用的挑戰。

此外，將組學技術整合到臨床實踐中還面臨報銷政策和醫療保健系統準備方面的障礙。展示基於組學的診斷和治療的臨床實用性和成本效益對於確保保險提供者的報銷並獲得醫療機構的認可至關重要。此外，跨學科合作和勞動力培訓的需求也帶來了挑戰。組學技術通常需要生物學家、生物資訊學家、資料分析師和臨床醫生之間的合作。確保這些不同學科的專業人員接受培訓並能夠有效地合作是一項複雜的任務。應對組學技術實施緩慢的挑戰需要政府、研究機構和產業利益相關者的共同努力。對基礎設施、監管框架、勞動力發展和研究夥伴關係的投資可以加速組學技術與各種應用的整合，最終實現其推進科學知識和改善患者護理的潛力。

主要市場趨勢

個人化醫療

個人化醫療是組學實驗室服務市場的變革趨勢，重新定義了醫療保健的處理和提供方式。這一趨勢的推動是因為人們認知到一刀切的醫療方法可能並不是對每個患者來說都是最有效的方法。相反，個人化醫療利用組學技術的力量，根據個體獨特的遺傳、基因組和分子特徵量身定做醫療干涉措施。個人化醫療的關鍵驅動力之一是組學實驗室服務使精確診斷成為可能。透過基因組學、蛋白質組學和代謝組學等組學分析，醫療保健提供者可以全面了解患者的生物學狀況。這些資訊可以識別每個人特有的遺傳變異、疾病標記和治療目標。

個人化醫療在腫瘤學中尤其明顯，透過組學技術進行腫瘤分析可指導治療決策。透過了解導致患者癌症的基因突變，腫瘤學家可以選擇更有可能有效的標靶治療，最大限度地減少副作用並提高存活率。此外，個人化醫療的趨勢已從癌症擴展到各個醫學領域，包括心臟病學、神經病學和罕見疾病。組學實驗室服務能夠識別疾病的遺傳傾向，從而採取早期干涉和預防措施。直接面對消費者 (DTC) 組學測試的興起也有助於個人化醫療的成長。 DTC 服務使個人能夠獲取其遺傳訊息，從而提高對遺傳和健康風險因素的認知。這種意識的提高使個人能夠做出明智的生活方式選擇並積極主動地進行健康管理。

人工智慧 (AI) 和機器學習在使個人化醫療變得可行方面發揮著關鍵作用。這些技術有助於分析大量的組學資料集、識別模式並預測疾病風險或治療反應，所有這些對於為個人量身定做醫療護理至關重要。總之，在更有效、以病人為中心的醫療保健承諾的推動下，個人化醫療是組學實驗室服務市場的一個引人注目的趨勢。隨著組學技術的不斷進步和變得更加容易獲得，個人化醫療有望在醫療保健中發揮越來越重要的作用，提供改善治療結果、減少不良反應並最終提高患者護理品質的潛力。

多組學整合

多組學整合是組學實驗室服務市場的一個重要的變革性趨勢，徹底改變了我們對生物學和疾病的理解。這一趨勢涉及同時分析和整合來自不同組學學科的資料，包括基因組學、蛋白質組學、代謝組學、轉錄組學和表觀基因組學。它對於揭示複雜的生物機制、識別新型生物標記和推進精準醫學具有巨大的前景。

多組學整合背後的驅動力之一是認知到沒有任何單一學科可以提供生物系統的完整圖像。每個組學層都提供了對細胞功能和分子相互作用的不同方面的獨特見解。整合這些層使研究人員和臨床醫生能夠更全面地了解疾病、生物途徑和治療標靶。例如，在癌症研究中，多組學整合可以揭示驅動腫瘤生長的基因突變（基因組學）、導致疾病進展的蛋白質表現模式（蛋白質體學）以及與治療反應或抗藥性相關的代謝變化（代謝組學）。這種整體見解可以指導針對個別患者的多組學特徵制定個人化治療策略。高通量組學技術和資料分析工具的進步使得多組學整合變得越來越可行。研究人員現在可以產生包含多個組學層的大量資料集，而複雜的生物資訊方法有助於這些複雜資料的整合和解釋。

多組學整合的趨勢不僅限於研究。它也在臨床診斷和個人化醫療中得到應用。臨床醫生可以將基因組學資料與蛋白質組學或代謝組學資料結合，以做出更準確的疾病診斷，預測患者對特定治療的反應，並識別潛在的副作用或不良反應。此外，多組學方法對於研究多種生物因素相互作用的複雜疾病至關重要，例如神經退化性疾病、自體免疫疾病和心血管疾病。這些方法揭示了先前在檢查單一組學層時隱藏的新疾病機制和生物標記。總之，多組學整合是組學實驗室服務市場的變革趨勢，提供對生物學和疾病更深入、更全面的理解。隨著技術不斷進步和資料整合變得更加複雜，多組學方法在推動研究、診斷和個人化醫療創新方面的潛力巨大，有望重塑醫療保健和科學發現的格局。

細分市場洞察

服務洞察

由於幾個令人信服的原因，蛋白質體學領域在組學實驗室服務市場中佔有最大的佔有率。首先，蛋白質體學是理解生物系統功能的基礎。它專注於蛋白質的研究，蛋白質是細胞的主力，在各種生物過程中發揮關鍵作用。分析蛋白質的能力可以深入了解其結構、功能、相互作用、修飾和表達水平，揭示細胞和生物體如何回應不同的刺激和疾病。其次，蛋白質體學領域與藥物發現和開發高度相關。它能夠識別潛在的藥物標靶、評估藥物功效和安全性以及研究與疾病相關的蛋白質生物標記。該應用吸引了製藥和生物技術公司的大量投資，推動了對蛋白質體學服務的需求。

第三，蛋白質體學領域受益於質譜和液相層析技術的進步，提高了蛋白質分析的準確性、靈敏度和通量。這些技術進步使蛋白質體學服務更容易獲得且更具成本效益。此外，個人化醫療領域嚴重依賴蛋白質體學資料。透過分析個人的蛋白質概況，醫療保健提供者可以根據特定患者的需求量身定做治療和介入措施，最佳化治療結果並最大限度地減少副作用。總之，蛋白質體學領域在組學實驗室服務市場中的主導地位歸因於其在揭示生物系統功能複雜性方面的核心作用、其在藥物發現中的重要性以及其對新興的個人化醫療時代的貢獻。隨著蛋白質體學技術的不斷進步，該領域有望保持其領先地位，推動醫療保健、研究和診斷領域的創新和進步。

商業洞察

診斷實驗室在組學實驗室服務市場中佔據最大佔有率，因為它們在將組學技術轉化為患者護理和疾病管理的可行見解方面發揮關鍵作用。首先，診斷實驗室處於組學技術臨床應用的最前線。他們為診斷疾病、評估疾病風險和監測患者對治療的反應提供基本服務。這種臨床相關性使診斷實驗室成為醫療保健系統的重要組成部分。其次，對個人化醫療和精準診斷的需求不斷成長，推動了診斷實驗室的發展。基因組學和蛋白​​質組學等組學技術提供了根據患者獨特的分子譜為個別患者量身定做醫療治療的潛力。診斷實驗室在提供這些個人化診斷服務方面發揮核心作用。第三，診斷實驗室配備了必要的基礎設施、儀器和專業知識，可以準確地處理和處理生物樣本以進行組學分析。他們建立了品質控制措施並遵守監管標準，確保測試結果的可靠性和準確性。

此外，診斷實驗室是科學研究和臨床實踐之間的橋樑。他們驗證並實施在研究環境中開發的基於組學的測試和測定，使它們可供醫療保健提供者和患者使用。總之，診斷實驗室在組學實驗室服務市場中的主導地位源於其在臨床診斷、個人化醫療以及將組學資料轉化為現實世界患者護理方面的關鍵作用。隨著組學技術不斷進步並日益融入醫療保健，診斷實驗室有望保持其領先地位，塑造精準醫療和疾病管理的未來。

區域洞察

由於多種因素的融合，北美在組學實驗室服務市場中佔據了最大的佔有率，這些因素促成了該地區在組學科學和實驗室服務領域的領導地位。首先，北美擁有強大的研究生態系統，擁有世界知名的學術機構、研究組織和生物技術中心。這些機構一直處於組學研究的前沿，推動基因組學、蛋白質組學、代謝組學和其他組學學科的創新和技術進步。這種卓越的研究成果轉化為學術和工業環境對組學實驗室服務的強烈需求。其次，該地區擁有完善的醫療基礎設施和較高的醫療支出水準。這促進了組學技術融入臨床實踐，實現個人化醫療和精準診斷。北美的醫療保健提供者擴大採用基於組學的測試和服務來改善患者的治療結果。

第三，北美的生物技術和製藥業是組學實驗室服務市場的主要驅動力。這些產業在藥物發現、開發和臨床試驗方面投入巨資，依靠組學資料來識別藥物標靶、評估藥物療效並對患者群體進行分層。此外，該地區的監管環境有利於基於組學的診斷和治療的開發和商業化。美國 FDA 等監管機構為組學驅動的醫療產品的批准提供了明確的途徑，促進了市場的成長。總之，北美在組學實驗室服務市場的領先地位可歸因於其強大的研究基礎、先進的醫療保健系統、蓬勃發展的生物技術產業和支持性的監管框架。這些因素共同推動該地區走在組學科學和實驗室服務的前沿，推動醫療保健、研究和診斷領域的創新和進步。

目錄

第 1 章：服務概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：客戶之聲

第 5 章：全球組學實驗室服務市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依服務分類（基因組學、蛋白質組學、轉錄組學、代謝組學、表觀遺傳學）
    • 按服務頻率（拋棄式、重複、連續）
    • 按業務（醫院、研究所、診斷實驗室）
    • 依最終用途（癌症、藥物、生殖、其他遺傳疾病）
    • 按公司分類 (2022)
    • 按地區
  • 市場地圖

第 6 章：北美組學實驗室服務市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按服務
    • 按服務頻率
    • 按業務分類
    • 按最終用途
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第 7 章：歐洲組學實驗室服務市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按服務
    • 按服務頻率
    • 按業務分類
    • 按最終用途
    • 按國家/地區
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第 8 章：亞太組學實驗室服務市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按服務
    • 按服務頻率
    • 按業務分類
    • 按最終用途
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲

第 9 章：南美洲組學實驗室服務市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按服務
    • 按服務頻率
    • 按業務分類
    • 按最終用途
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲組學實驗室服務市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按服務
    • 按服務頻率
    • 按業務分類
    • 按最終用途
    • 按國家/地區
  • MEA：國家分析
    • 南非組學實驗室服務
    • 沙烏地阿拉伯組學實驗室服務
    • 阿拉伯聯合大公國組學實驗室服務

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

  • 最近的發展
  • 產品發布
  • 併購

第 13 章：大環境分析

第 14 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第15章：競爭格局

  • 商業概覽
  • 公司概況
  • 產品與服務
  • 財務（上市公司）
  • 最近的發展
  • SWOT分析
    • AGILENT TECHNOLOGIES, INC.
    • Q2 Solutions LLC
    • FLOMICS BIOTECH
    • QIAGEN NV
    • THERMO FISHER SCIENTIFIC, INC
    • ILLUMINA, INC
    • QUEST DIAGNOSTICS INCORPORATED
    • PHENOSWITCH BIOSCIENCE
    • Spectrus Corporation
    • BEIJING GENOMICS INSTITUTE

第 16 章：策略建議

簡介目錄
Product Code: 16260

In 2022, the Global Omics Lab Services Market was valued at an impressive USD 71.23 billion, and it is poised to reach a robust Compound Annual Growth Rate (CAGR) of 9.53% through 2028. The Omics Lab Services Market stands out as a dynamic and integral segment within the constantly evolving realm of omics sciences.

Within this market, a diverse array of services is offered, encompassing everything from genomics to proteomics, metabolomics, and beyond. These services assume a pivotal role in unraveling the intricacies of biological systems, uncovering genetic variations, and delving into biomarkers for the diagnosis and treatment of diseases.

The market's growth is propelled by several key factors, including:

Market Overview
Forecast Period2024-2028
Market Size 2022USD 71.23 Billion
Market Size 2028USD 123.99 Billion
CAGR 2023-20289.53%
Fastest Growing SegmentCancer
Largest MarketNorth America
  • 1. Surging Demand for Personalized Medicine: The escalating demand for personalized medicine fuels the expansion of omics lab services, as they are instrumental in tailoring medical treatments to individual genetic profiles.
  • 2. Advancements in High-Throughput Technologies: Continuous advancements in high-throughput technologies enhance the efficiency and effectiveness of omics lab services, enabling researchers to analyze vast amounts of biological data swiftly and accurately.
  • 3. Need for Comprehensive Data Analysis: Omics lab services are indispensable in comprehensively analyzing biological data, making them vital in various fields, including drug discovery, agriculture, and environmental research.

As the pursuit of precision medicine and a deeper comprehension of biological systems intensifies, the Omics Lab Services Market continues to broaden its capabilities and exert a significant influence across a multitude of scientific disciplines.

Key Market Drivers

Growing Integration Of Genomics Data Into Clinical Workflows

The integration of genomics data into clinical workflows is driving a significant transformation in healthcare and is a key driver of the Omics Lab Services Market. This integration is revolutionizing the way healthcare is practiced, from disease diagnosis and treatment selection to monitoring patient outcomes. Several factors contribute to the growing importance of integrating genomics data into clinical practice and its subsequent impact on omics lab services. Firstly, genomics data provides a comprehensive understanding of an individual's genetic makeup. This includes identifying genetic variations, mutations, and predispositions to diseases. This information is invaluable in tailoring medical treatments and interventions to each patient's unique genetic profile, a concept known as precision medicine. As genomics data becomes more accessible and affordable, its integration into clinical workflows becomes increasingly practical and desirable. Secondly, genomics data plays a pivotal role in disease diagnosis and risk assessment. It enables healthcare providers to identify genetic markers associated with various medical conditions, allowing for early disease detection and personalized treatment strategies. For example, genomics data can help predict an individual's susceptibility to certain cancers, cardiovascular diseases, or rare genetic disorders. Thirdly, the advancement of high-throughput sequencing technologies and bioinformatics tools has made it more feasible to generate and interpret genomics data quickly and accurately. This facilitates the seamless integration of genomics information into clinical decision-making processes. Omics lab services providers are at the forefront of these technological advancements, offering the expertise and infrastructure needed to process, analyze, and interpret genomics data efficiently.

Moreover, genomics data integration extends beyond diagnosis and treatment selection. It also encompasses the monitoring of patient responses to therapies, the identification of potential drug targets, and the discovery of novel biomarkers. These applications further highlight the relevance and growing demand for omics lab services in translating genomics data into actionable insights within clinical settings. In conclusion, the integration of genomics data into clinical workflows is ushering in an era of precision medicine, where healthcare is tailored to individual genetic profiles. This transformation is bolstering the demand for omics lab services, as they are instrumental in generating, analyzing, and interpreting genomics data for better-informed clinical decisions and improved patient outcomes. As healthcare continues to evolve, omics lab services are positioned at the forefront of this transformative journey.

Rising Adoption Of Direct-To-Consumer Omics

The rising adoption of Direct-To-Consumer (DTC) omics services is significantly driving the growth of the Omics Lab Services Market. DTC omics services empower individuals to access and interpret their genetic, genomic, and other omics information directly from specialized laboratories, without the need for healthcare provider intermediaries. This trend has gained momentum due to several compelling factors, profoundly impacting both consumers and the omics lab services industry.

Firstly, DTC omics services offer consumers unparalleled insights into their genetic makeup and health predispositions. This accessibility and transparency empower individuals to take a proactive role in managing their health, making informed lifestyle choices, and considering personalized preventive measures. As consumers become more health-conscious and curious about their genetic heritage, the demand for these services has surged. Secondly, the convenience of DTC omics services cannot be overstated. Consumers can easily order genetic testing kits online, collect their samples at home, and send them to specialized omics laboratories for analysis. This streamlined process eliminates barriers such as the need for a healthcare provider's prescription and multiple clinic visits, making omics testing more accessible than ever before. Thirdly, the proliferation of DTC omics services has expanded the market for omics lab services providers. These specialized labs play a pivotal role in processing and analyzing the vast amount of data generated from consumer samples. They offer expertise in ensuring data accuracy, privacy, and security, which is essential for consumer trust. Moreover, DTC omics services have fostered an environment of data sharing and research participation. Many consumers opt to contribute their anonymized data to research projects, further advancing scientific knowledge and potentially leading to breakthroughs in genomics and personalized medicine. Omics lab services providers are key facilitators in managing and analyzing these expansive datasets.

However, the growth of DTC omics services also raises ethical, privacy, and regulatory considerations that omics labs must navigate. Ensuring data security, privacy protection, and responsible interpretation of results are paramount. In conclusion, the rising adoption of DTC omics services has democratized access to genomic and omics information, profoundly impacting both consumers and the omics lab services market. As individuals increasingly seek to understand their genetic makeup and its implications for health and ancestry, omics lab services providers are poised to play a pivotal role in satisfying this demand, while also contributing to scientific research and advancements in personalized medicine.

Rising Demand For Early Disease Diagnostic Tests

The Omics Lab Services Market is experiencing robust growth, driven by the escalating demand for early disease diagnostic tests. This demand surge is fueled by several interrelated factors that underscore the critical role of omics lab services in the landscape of early disease detection and prevention.

Firstly, there is a growing recognition of the profound impact that early disease diagnosis can have on patient outcomes. Early detection enables timely intervention and treatment, often when the disease is at a more manageable and curable stage. As a result, healthcare systems, clinicians, and patients are increasingly prioritizing early diagnostic tests to improve prognosis and survival rates. Secondly, advancements in omics technologies have revolutionized the field of diagnostic testing. Techniques like genomics, proteomics, and metabolomics allow for comprehensive and precise profiling of biomarkers associated with various diseases. These technologies provide a deep understanding of the molecular and genetic underpinnings of diseases, enhancing diagnostic accuracy and enabling the development of targeted therapies. Thirdly, the rising prevalence of chronic and lifestyle-related diseases, such as cancer, diabetes, and cardiovascular disorders, has heightened the need for early diagnostic tests. These diseases often progress silently in their early stages, making early detection through biomarker analysis a crucial strategy for disease management and prevention.

Additionally, healthcare policies and public health initiatives are increasingly promoting regular screenings and early diagnostic tests as part of preventive healthcare. The emphasis on proactive health management and disease prevention has led to a surge in demand for diagnostic services offered by omics lab services providers. Furthermore, the COVID-19 pandemic has underscored the importance of early disease diagnosis. Rapid diagnostic tests and the sequencing of the SARS-CoV-2 virus's genome have been instrumental in identifying and managing the virus's spread. This experience has highlighted the critical role that omics lab services can play in responding to emerging infectious diseases and facilitating timely public health interventions. In summary, the rising demand for early disease diagnostic tests is a compelling driver of the Omics Lab Services Market. As healthcare systems and patients increasingly recognize the value of early detection, omics lab services providers are poised to play a pivotal role in delivering accurate and timely diagnostic solutions, ultimately improving patient outcomes and public health.

Technological Advancements

Technological advancements are a driving force behind the growth and evolution of the Omics Lab Services Market. These advancements span multiple dimensions, encompassing innovations in laboratory instrumentation, data analysis, high-throughput techniques, and automation. Their impact on omics lab services is profound and multi-faceted. Firstly, technological advancements have significantly improved the accuracy and efficiency of omics analyses. High-throughput sequencing platforms, for example, have revolutionized genomics research and diagnostics by enabling the rapid and cost-effective sequencing of DNA and RNA. This has opened doors to a wealth of information for researchers and healthcare providers, facilitating precise diagnosis, treatment selection, and disease monitoring. Secondly, automation and robotics have streamlined laboratory workflows, increased throughput and reducing the potential for human errors. Automated liquid handling systems, sample preparation robots, and high-content imaging systems have become integral components of omics lab services, enhancing reliability and reproducibility.

Thirdly, advances in data analysis and bioinformatics have been pivotal in managing the vast amounts of data generated by omics technologies. Machine learning algorithms, big data analytics, and cloud computing have accelerated the interpretation of omics data, enabling the identification of meaningful patterns, biomarkers, and therapeutic targets. Moreover, miniaturization and microfluidics technologies have enabled the development of compact and portable lab-on-a-chip devices. These innovations are particularly valuable in point-of-care diagnostics and resource-limited settings, expanding the reach of omics lab services to diverse healthcare environments. Furthermore, technological advancements have fostered the integration of multiple omics disciplines, such as genomics, proteomics, and metabolomics. This multi-omics approach provides a holistic understanding of biological systems and diseases, offering more comprehensive diagnostic insights and personalized treatment strategies.

In the era of precision medicine, technological advancements are enabling the development of targeted therapies based on an individual's unique omics profile. This patient-centric approach is reshaping healthcare delivery, with omics lab services at its core. In conclusion, technological advancements are driving the Omics Lab Services Market by enhancing the precision, efficiency, and scope of omics analyses. These innovations are propelling the field of personalized medicine and expanding the applications of omics lab services across healthcare, research, and diagnostics, ultimately leading to improved patient outcomes and scientific advancements.

Key Market Challenges

Lack Of Skilled Professionals

The Omics Lab Services Market is encountering a significant challenge in the form of a shortage of skilled professionals. This challenge is multifaceted and has repercussions on the industry's ability to fully harness the potential of omics technologies and meet the growing demand for services. Firstly, the complexity of omics analyses requires specialized training and expertise. Professionals in this field need to possess a deep understanding of molecular biology, bioinformatics, instrumentation, and data analysis. With rapid advancements in technology and methodologies, staying current with the latest developments is essential. Unfortunately, there is a gap in the availability of professionals with this level of expertise. Secondly, the shortage of skilled professionals is particularly evident in the realm of bioinformatics. Managing and interpreting the vast amounts of data generated by omics technologies necessitates proficiency in bioinformatics tools and data analysis. The scarcity of bioinformaticians and computational biologists can result in bottlenecks in data analysis, leading to delays in research and diagnostics. Moreover, the interdisciplinary nature of omics sciences requires collaboration among experts in various fields, including biology, chemistry, informatics, and clinical research. The shortage of professionals who can effectively communicate and collaborate across these disciplines hinders the seamless integration of omics technologies into healthcare and research.

The education and training pipeline for omics professionals also faces challenges. Universities and training programs must keep pace with the rapid evolution of omics technologies to produce graduates with relevant skills. Additionally, hands-on training opportunities and mentorship programs are essential to bridge the gap between academic knowledge and practical laboratory skills. Furthermore, the global competition for skilled omics professionals intensifies the challenge. Biotechnology and pharmaceutical companies, academic institutions, and healthcare providers are all vying for the same talent pool, creating a competitive environment that can drive up labor costs. Addressing the shortage of skilled professionals in the Omics Lab Services Market is crucial for the industry's sustained growth and innovation. Initiatives such as expanding educational programs, offering continuing education opportunities, and promoting interdisciplinary collaboration can help mitigate this challenge and ensure that the potential of omics technologies is fully realized in healthcare, research, and diagnostics.

Slow Implementation Of Omics Technology

The slow implementation of omics technology poses a significant challenge to the Omics Lab Services Market. This challenge is multifaceted and encompasses various factors that hinder the adoption and integration of omics technologies into research, diagnostics, and healthcare. Firstly, the pace of technological advancement in the omics field is rapid, and keeping up with the latest innovations can be challenging for laboratories and healthcare institutions. Omics technologies continually evolve, introducing new techniques, instruments, and analytical methods. This rapid evolution can create a barrier for some laboratories that may lack the resources or infrastructure to swiftly implement and validate these technologies. Secondly, the complexity of omics data generation and analysis requires not only specialized equipment but also the development of tailored laboratory workflows and data management systems. The slow adaptation of these infrastructural components can impede the efficient deployment of omics technologies, leading to delays in research and diagnostics. Thirdly, regulatory and ethical considerations play a role in the slow implementation of omics technology. Ensuring compliance with regulations related to data privacy, sample handling, and clinical validation is essential but can be time-consuming and resource-intensive. Moreover, addressing ethical concerns surrounding the use of omics data, particularly in areas like genomics, can pose challenges that delay the adoption of these technologies.

Additionally, the integration of omics technologies into clinical practice faces hurdles related to reimbursement policies and healthcare system readiness. Demonstrating the clinical utility and cost-effectiveness of omics-based diagnostics and treatments is essential for securing reimbursement from insurance providers and gaining acceptance within healthcare institutions. Furthermore, the need for interdisciplinary collaboration and workforce training presents challenges. Omics technologies often require collaboration among biologists, bioinformaticians, data analysts, and clinicians. Ensuring that professionals across these diverse disciplines are trained and can effectively work together is a complex task. Addressing the challenge of slow omics technology implementation requires a concerted effort from governments, research institutions, and industry stakeholders. Investing in infrastructure, regulatory frameworks, workforce development, and research partnerships can accelerate the integration of omics technologies into various applications, ultimately realizing their potential to advance scientific knowledge and improve patient care.

Key Market Trends

Personalized Medicine

Personalized medicine is a transformative trend in the Omics Lab Services Market, redefining the way healthcare is approached and delivered. This trend is driven by the realization that one-size-fits-all medical treatments may not be the most effective approach for every patient. Instead, personalized medicine leverages the power of omics technologies to tailor medical interventions to an individual's unique genetic, genomic, and molecular profile. One of the key drivers of personalized medicine is the advent of precision diagnostics made possible by omics lab services. Through omics analyses such as genomics, proteomics, and metabolomics, healthcare providers gain comprehensive insights into a patient's biology. This information allows for the identification of genetic variations, disease markers, and therapeutic targets specific to each individual.

Personalized medicine is particularly evident in oncology, where tumor profiling through omics technologies guides treatment decisions. By understanding the genetic mutations driving a patient's cancer, oncologists can select targeted therapies that are more likely to be effective, minimizing side effects and improving survival rates. Moreover, the trend towards personalized medicine extends beyond cancer to various medical fields, including cardiology, neurology, and rare diseases. Omics lab services enable the identification of genetic predispositions to diseases, allowing for early interventions and preventive measures. The rise of direct-to-consumer (DTC) omics testing also contributes to personalized medicine's growth. DTC services provide individuals with access to their genetic information, fostering greater awareness of genetics and health risk factors. This heightened awareness empowers individuals to make informed lifestyle choices and engage in proactive health management.

Artificial intelligence (AI) and machine learning play a pivotal role in making personalized medicine actionable. These technologies help analyze vast omics datasets, identify patterns, and predict disease risk or treatment responses, all of which are essential for tailoring medical care to the individual. In conclusion, personalized medicine is a compelling trend in the Omics Lab Services Market, driven by the promise of more effective, patient-centered healthcare. As omics technologies continue to advance and become more accessible, personalized medicine is poised to play an increasingly prominent role in healthcare, offering the potential to improve treatment outcomes, reduce adverse effects, and ultimately enhance the quality of patient care.

Multi-Omics Integration

Multi-omics integration is a significant and transformative trend in the Omics Lab Services Market, revolutionizing our understanding of biology and disease. This trend involves the simultaneous analysis and integration of data from various omics disciplines, including genomics, proteomics, metabolomics, transcriptomics, and epigenomics. It holds immense promise for uncovering complex biological mechanisms, identifying novel biomarkers, and advancing precision medicine.

One of the driving forces behind multi-omics integration is the realization that no single omics discipline provides a complete picture of biological systems. Each omics layer offers unique insights into different aspects of cellular function and molecular interactions. Integrating these layers allows researchers and clinicians to gain a more comprehensive understanding of diseases, biological pathways, and therapeutic targets. For example, in cancer research, multi-omics integration can reveal the genetic mutations (genomics) driving tumor growth, the protein expression patterns (proteomics) responsible for disease progression, and the metabolic changes (metabolomics) associated with treatment response or resistance. Such holistic insights can guide the development of personalized treatment strategies tailored to an individual patient's multi-omics profile. Advancements in high-throughput omics technologies and data analysis tools have made multi-omics integration increasingly feasible. Researchers can now generate massive datasets encompassing multiple omics layers, and sophisticated bioinformatics approaches facilitate the integration and interpretation of these complex data.

The trend towards multi-omics integration is not limited to research. It is also finding applications in clinical diagnostics and personalized medicine. Clinicians can combine genomics data with proteomics or metabolomics data to make more accurate disease diagnoses, predict patient responses to specific treatments, and identify potential side effects or adverse reactions. Moreover, multi-omics approaches are crucial for studying complex diseases, such as neurodegenerative disorders, autoimmune conditions, and cardiovascular diseases, where multiple biological factors interplay. These approaches are uncovering novel disease mechanisms and biomarkers that were previously hidden when examining single omics layers. In conclusion, multi-omics integration is a transformative trend in the Omics Lab Services Market, offering a deeper and more holistic understanding of biology and disease. As technology continues to advance and data integration becomes more sophisticated, the potential for multi-omics approaches to drive innovation in research, diagnostics, and personalized medicine is substantial, promising to reshape the landscape of healthcare and scientific discovery.

Segmental Insights

Service Insights

The Proteomics segment has held the largest share in the Omics Lab Services Market due to several compelling reasons. Firstly, proteomics is fundamental to understanding the functional aspects of biological systems. It focuses on the study of proteins, which are the workhorses of cells and play critical roles in various biological processes. The ability to analyze proteins provides insights into their structures, functions, interactions, modifications, and expression levels, shedding light on how cells and organisms respond to different stimuli and diseases. Secondly, the proteomics segment is highly relevant in drug discovery and development. It enables the identification of potential drug targets, the assessment of drug efficacy and safety, and the investigation of protein biomarkers associated with diseases. This application has attracted significant investments from pharmaceutical and biotechnology companies, driving demand for proteomics services.

Thirdly, the proteomics segment benefits from advancements in mass spectrometry and liquid chromatography techniques, which have improved the accuracy, sensitivity, and throughput of protein analysis. These technological advancements have made proteomics services more accessible and cost-effective. Moreover, the field of personalized medicine relies heavily on proteomics data. By analyzing an individual's protein profile, healthcare providers can tailor treatments and interventions to specific patient needs, optimizing therapeutic outcomes and minimizing side effects. In conclusion, the Proteomics segment's dominance in the Omics Lab Services Market is attributed to its central role in unraveling the functional complexities of biological systems, its significance in drug discovery, and its contributions to the emerging era of personalized medicine. As proteomics technologies continue to advance, this segment is poised to maintain its leading position, driving innovation and advancements in healthcare, research, and diagnostics.

Business Insights

Diagnostic laboratories have held the largest share in the Omics Lab Services Market due to their pivotal role in translating omics technologies into actionable insights for patient care and disease management. Firstly, diagnostic labs are at the forefront of clinical applications for omics technologies. They provide essential services for diagnosing diseases, assessing disease risk, and monitoring patient responses to treatments. This clinical relevance has positioned diagnostic labs as a critical component of the healthcare system. Secondly, the rising demand for personalized medicine and precision diagnostics has propelled the growth of diagnostic labs. Omics technologies, such as genomics and proteomics, offer the potential to tailor medical treatments to individual patients based on their unique molecular profiles. Diagnostic labs play a central role in delivering these personalized diagnostic services. Thirdly, diagnostic labs are equipped with the necessary infrastructure, instruments, and expertise to handle and process biological samples for omics analysis accurately. They have established quality control measures and adhere to regulatory standards, ensuring the reliability and accuracy of test results.

Moreover, diagnostic labs serve as a bridge between scientific research and clinical practice. They validate and implement omics-based tests and assays developed in research settings, making them available to healthcare providers and patients. In conclusion, diagnostic labs' dominance in the Omics Lab Services Market stems from their critical role in clinical diagnostics, personalized medicine, and translating omics data into real-world patient care. As omics technologies continue to advance and become increasingly integrated into healthcare, diagnostic labs are poised to maintain their leading position, shaping the future of precision medicine and disease management.

Regional Insights

North America has held the largest share in the Omics Lab Services Market due to a convergence of factors that have contributed to the region's leadership in the field of omics sciences and laboratory services. Firstly, North America boasts a robust research ecosystem with world-renowned academic institutions, research organizations, and biotechnology hubs. These institutions have been at the forefront of omics research, driving innovation and technological advancements in genomics, proteomics, metabolomics, and other omics disciplines. This research excellence has translated into a strong demand for omics lab services in both academic and industrial settings. Secondly, the region has a well-established healthcare infrastructure and a high level of healthcare expenditure. This has facilitated the integration of omics technologies into clinical practice, enabling personalized medicine and precision diagnostics. Healthcare providers in North America are increasingly adopting omics-based tests and services to improve patient outcomes.

Thirdly, North America's biotechnology and pharmaceutical industry is a major driver of the omics lab services market. These industries heavily invest in drug discovery, development, and clinical trials, relying on omics data to identify drug targets, assess drug efficacy, and stratify patient populations. Moreover, the region's regulatory environment is conducive to the development and commercialization of omics-based diagnostics and therapies. Regulatory bodies such as the FDA in the United States have provided clear pathways for the approval of omics-driven medical products, fostering growth in the market. In conclusion, North America's leadership in the Omics Lab Services Market can be attributed to its strong research foundation, advanced healthcare system, thriving biotechnology sector, and supportive regulatory framework. These factors have collectively propelled the region to the forefront of omics sciences and laboratory services, driving innovation and advancements in healthcare, research, and diagnostics.

Key Market Players

  • AGILENT TECHNOLOGIES, INC.
  • Q2 Solutions LLC
  • FLOMICS BIOTECH
  • QIAGEN NV
  • THERMO FISHER SCIENTIFIC, INC
  • ILLUMINA, INC
  • QUEST DIAGNOSTICS INCORPORATED
  • PHENOSWITCH BIOSCIENCE
  • Spectrus Corporation
  • BEIJING GENOMICS INSTITUTE.

Report Scope:

In this report, the Global Omics Lab Services Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Omics Lab Services Market, By Service:

  • Genomics
  • Proteomics
  • Transcriptomics
  • Metabolomics
  • Epigenetics

Omics Lab Services Market, By Frequency Of Service:

  • One-Off
  • Repeat
  • Continuous

Omics Lab Services Market, By Business:

  • Hospitals
  • Research Institutes
  • Diagnostic Labs

Omics Lab Services Market, By End Use:

  • Cancer
  • Pharmaco
  • Reproductive
  • Other Genetic Disease

Omics Lab Services Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Turkey
  • Egypt

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Omics Lab Services Market.

Available Customizations:

  • Global Omics Lab Services market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Service Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customers

5. Global Omics Lab Services Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Service (Genomics, Proteomics, Transcriptomics, Metabolomics, Epigenetics)
    • 5.2.2. By Frequency Of Service (One-Off, Repeat, Continuous)
    • 5.2.3. By Business (Hospitals, Research Institutes, Diagnostic Labs)
    • 5.2.4. By End Use (Cancer, Pharmaco, Reproductive, Other Genetic Disease)
    • 5.2.5. By Company (2022)
    • 5.2.6. By Region
  • 5.3. Market Map

6. North America Omics Lab Services Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Service
    • 6.2.2. By Frequency of Service
    • 6.2.3. By Business
    • 6.2.4. By End Use
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Omics Lab Services Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Service
        • 6.3.1.2.2. By Frequency of Service
        • 6.3.1.2.3. By Business
        • 6.3.1.2.4. By End Use
    • 6.3.2. Mexico Omics Lab Services Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Service
        • 6.3.2.2.2. By Frequency of Service
        • 6.3.2.2.3. By Business
        • 6.3.2.2.4. By End Use
    • 6.3.3. Canada Omics Lab Services Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Service
        • 6.3.3.2.2. By Frequency of Service
        • 6.3.3.2.3. By Business
        • 6.3.3.2.4. By End Use

7. Europe Omics Lab Services Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Service
    • 7.2.2. By Frequency of Service
    • 7.2.3. By Business
    • 7.2.4. By End Use
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Omics Lab Services Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Service
        • 7.3.1.2.2. By Frequency of Service
        • 7.3.1.2.3. By Business
        • 7.3.1.2.4. By End Use
    • 7.3.2. Germany Omics Lab Services Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Service
        • 7.3.2.2.2. By Frequency of Service
        • 7.3.2.2.3. By Business
        • 7.3.2.2.4. By End Use
    • 7.3.3. United Kingdom Omics Lab Services Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Service
        • 7.3.3.2.2. By Frequency of Service
        • 7.3.3.2.3. By Business
        • 7.3.3.2.4. By End Use
    • 7.3.4. Italy Omics Lab Services Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Service
        • 7.3.4.2.2. By Frequency of Service
        • 7.3.4.2.3. By Business
        • 7.3.4.2.4. By End Use
    • 7.3.5. Spain Omics Lab Services Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Service
        • 7.3.5.2.2. By Frequency of Service
        • 7.3.5.2.3. By Business
        • 7.3.5.2.4. By End Use

8. Asia-Pacific Omics Lab Services Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Service
    • 8.2.2. By Frequency of Service
    • 8.2.3. By Business
    • 8.2.4. By End Use
    • 8.2.5. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Omics Lab Services Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Service
        • 8.3.1.2.2. By Frequency of Service
        • 8.3.1.2.3. By Business
        • 8.3.1.2.4. By End Use
    • 8.3.2. India Omics Lab Services Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Service
        • 8.3.2.2.2. By Frequency of Service
        • 8.3.2.2.3. By Business
        • 8.3.2.2.4. By End Use
    • 8.3.3. South Korea Omics Lab Services Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Service
        • 8.3.3.2.2. By Frequency of Service
        • 8.3.3.2.3. By Business
        • 8.3.3.2.4. By End Use
    • 8.3.4. Japan Omics Lab Services Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Service
        • 8.3.4.2.2. By Frequency of Service
        • 8.3.4.2.3. By Business
        • 8.3.4.2.4. By End Use
    • 8.3.5. Australia Omics Lab Services Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Service
        • 8.3.5.2.2. By Frequency of Service
        • 8.3.5.2.3. By Business
        • 8.3.5.2.4. By End Use

9. South America Omics Lab Services Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Service
    • 9.2.2. By Frequency of Service
    • 9.2.3. By Business
    • 9.2.4. By End Use
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Omics Lab Services Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Service
        • 9.3.1.2.2. By Frequency of Service
        • 9.3.1.2.3. By Business
        • 9.3.1.2.4. By End Use
    • 9.3.2. Argentina Omics Lab Services Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Service
        • 9.3.2.2.2. By Frequency of Service
        • 9.3.2.2.3. By Business
        • 9.3.2.2.4. By End Use
    • 9.3.3. Colombia Omics Lab Services Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Service
        • 9.3.3.2.2. By Frequency of Service
        • 9.3.3.2.3. By Business
        • 9.3.3.2.4. By End Use

10. Middle East and Africa Omics Lab Services Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Service
    • 10.2.2. By Frequency of Service
    • 10.2.3. By Business
    • 10.2.4. By End Use
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Omics Lab Services Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Service
        • 10.3.1.2.2. By Frequency of Service
        • 10.3.1.2.3. By Business
        • 10.3.1.2.4. By End Use
    • 10.3.2. Saudi Arabia Omics Lab Services Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Service
        • 10.3.2.2.2. By Frequency of Service
        • 10.3.2.2.3. By Business
        • 10.3.2.2.4. By End Use
    • 10.3.3. UAE Omics Lab Services Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Service
        • 10.3.3.2.2. By Frequency of Service
        • 10.3.3.2.3. By Business
        • 10.3.3.2.4. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Company Snapshot
  • 15.3. Product & Services
  • 15.4. Financials (In case of listed companies)
  • 15.5. Recent Developments
  • 15.6. SWOT Analysis
    • 15.6.1. AGILENT TECHNOLOGIES, INC.
    • 15.6.2. Q2 Solutions LLC
    • 15.6.3. FLOMICS BIOTECH
    • 15.6.4. QIAGEN NV
    • 15.6.5. THERMO FISHER SCIENTIFIC, INC
    • 15.6.6. ILLUMINA, INC
    • 15.6.7. QUEST DIAGNOSTICS INCORPORATED
    • 15.6.8. PHENOSWITCH BIOSCIENCE
    • 15.6.9. Spectrus Corporation
    • 15.6.10. BEIJING GENOMICS INSTITUTE

16. Strategic Recommendations